Welcome to our dedicated page for Kinnate Biopharma news (Ticker: KNTE), a resource for investors and traders seeking the latest updates and insights on Kinnate Biopharma stock.
Kinnate Biopharma Inc. (Nasdaq: KNTE) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focusing on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers. Founded in 2018, Kinnate aims to address known oncogenic drivers for which there are currently no approved targeted therapies, and to overcome the limitations of existing cancer treatments, such as non-responsiveness and resistance.
The company's lead product candidate is EXARAFENIB, an investigational pan-RAF inhibitor targeting cancers with BRAF and NRAS-driven alterations. Another key candidate is KIN-3248, designed to treat cancers with FGFR2 and FGFR3 alterations. These candidates are part of the company's broader pipeline driven by the Kinnate Discovery Engine, which prioritizes high selectivity, optimized pharmaceutical properties, broad genetic alteration coverage, overcoming resistance, and brain penetration.
Recent achievements include FDA clearance for the IND application for KIN-7136, a brain-penetrant MEK inhibitor, and ongoing clinical trials for the exarafenib plus binimetinib combination. However, Kinnate has announced a strategic reprioritization plan, pausing the development of KIN-7136 and exploring strategic alternatives for exarafenib monotherapy and KIN-3248.
Financially, Kinnate reported having approximately $204.3 million in cash as of June 2023, projected to fund operations into the second quarter of 2026. Furthermore, the company has announced a workforce restructuring to align with its refined focus, aiming to retain around 28 full-time employees.
In terms of partnerships, Kinnate recently agreed to sell its investigational pan-RAF inhibitor, exarafenib, to Pierre Fabre Laboratories. This agreement is expected to expand the reach of Kinnate’s programs globally and maximize value for shareholders.
For more information, visit Kinnate.com and follow the company on LinkedIn to stay updated on their latest initiatives and corporate developments.
Kinnate Biopharma Inc. (Nasdaq: KNTE) has begun enrolling patients in the monotherapy expansion cohorts for its global Phase 1 clinical trial of exarafenib, a novel pan-RAF inhibitor. An oral presentation will showcase the initial safety and efficacy data at the American Association for Cancer Research (AACR) Annual Meeting on April 17, 2023. The trial specifically targets patients with BRAF-altered solid tumors and NRAS mutant melanoma. Kinnate's CEO emphasized the company's rapid progress, aiming to address the significant unmet needs in cancer treatment.
Kinnate Biopharma Inc. (Nasdaq: KNTE) announced the acquisition of Kinnjiu Biopharma Inc.'s ownership stake from Series A investors for $24 million. The deal includes Kinnjiu's cash, intellectual property, key personnel, and legal structure, enhancing Kinnate's capabilities in the oncology sector, especially in the People's Republic of China (PRC), Hong Kong, Macau, and Taiwan. Kinnate's current cash runway is projected to support operations until mid-2024. Additionally, Kinnate initiated the Phase 1 clinical trial for its pan-RAF inhibitor, exarafenib, with sites now open in the PRC and Taiwan.
Kinnate Biopharma (Nasdaq: KNTE) announced on February 14, 2023, that its investigational pan-FGFR inhibitor, KIN-3248, has received Fast Track designation from the FDA for treating unresectable, locally advanced, or metastatic cholangiocarcinoma (CCA) with FGFR2 gene alterations. This designation enables expedited drug development and review, addressing an urgent medical need for patients with prior systemic therapy. KIN-3248 targets key FGFR2/FGFR3 mutations linked to resistance in cancers like intrahepatic cholangiocarcinoma (ICC). The ongoing KN-4802 clinical trial aims to assess KIN-3248's safety and efficacy, with initial dose escalation data expected in H2 2023.
Kinnate Biopharma Inc. (Nasdaq: KNTE) announced that its CEO, Nima Farzan, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 14, 2023, at 1:40 p.m. ET. In addition, the Kinnate management team will hold investor meetings during the conference. Interested parties can access a live webcast of the session on the Kinnate website, with a replay available for 90 days post-event. Kinnate is dedicated to developing targeted therapies for cancer, focusing on oncogenic drivers that lack effective treatments. The company is advancing its clinical programs for solid tumors and aims to provide new, effective cancer therapies.
Kinnate Biopharma (Nasdaq: KNTE) appointed Jill DeSimone as an independent director, effective March 1, 2023. DeSimone has over 40 years of experience in life sciences, previously serving as President of U.S. Oncology at Merck, where she expanded annual revenues from $500 million to $9 billion. Her experience includes leading multiple product launches, including Keytruda. DeSimone expressed enthusiasm for joining Kinnate's board, emphasizing the company's unique approach to oncology. The board's chairman and CEO highlighted her expertise as a valuable addition during this transformative period for Kinnate.
Kinnate Biopharma (Nasdaq: KNTE) announced a poster presentation regarding the design and rationale of its ongoing Phase 1 trial (KN-4802) for the investigational pan-FGFR inhibitor, KIN-3248. This trial aims to assess safety, tolerability, and preliminary efficacy in adults with tumors harboring FGFR2 and/or FGFR3 gene alterations. KIN-3248 addresses oncogenic mutations prevalent in cancers like intrahepatic cholangiocarcinoma and urothelial carcinoma. The trial is open-label, involving 120 patients across the U.S. and Taiwan. Initial data is expected in the second half of 2023, with presentations at the ASCO conferences in January and February 2023.
Kinnate Biopharma Inc. (Nasdaq: KNTE) reported financial results for Q3 2022, highlighting a cash position of $262.1 million, projected to fund operations into mid-2024. The company is advancing its clinical programs, notably with KIN-2787, a pan-RAF inhibitor, currently in dose escalation in the Phase 1 trial. It received Fast Track designation from the FDA for KIN-2787 for treating specific melanoma patients. Q3 2022 net loss increased to $30.7 million from $24.7 million in Q3 2021, while R&D expenses rose to $23.5 million.
Kinnate Biopharma (KNTE) provided updates on its ongoing Phase 1 clinical trial KN-8701 for KIN-2787, a pan-RAF inhibitor. The trial is targeting patients with BRAF-altered solid tumors and NRAS mutant melanoma. KIN-2787 has cleared the predicted efficacious dose at 300 mg bid, with dose escalation ongoing. Initial clinical responses are encouraging, with results expected in the first half of 2023. As of September 30, 2022, Kinnate reported approximately $262 million in cash, providing a runway into mid-2024 to support its oncology programs.
Kinnate Biopharma (Nasdaq: KNTE) announced that the FDA has granted Fast Track designation for its investigational pan-RAF inhibitor, KIN-2787. This designation is for treating patients with BRAF Class II or III alteration-positive and/or NRAS mutation-positive metastatic melanoma. KIN-2787 is currently in a Phase 1 clinical trial targeting solid tumors with specific BRAF alterations. The FDA's Fast Track process aims to expedite the development and review of drugs meeting unmet medical needs. Kinnate also received Orphan Drug Designation for KIN-2787.
Kinnate Biopharma announced CEO Nima Farzan's participation in the Piper Sandler Heartland Summit on September 22, 2022. He will join a panel discussing FDA proposals that could impact oncology drug development. Kinnate is focused on precision oncology, developing targeted therapies for cancer patients. Their current programs target solid tumors with RAF, NRAS, and FGFR alterations, aiming to address unmet needs in cancer treatment. The company's ongoing commitment to innovation is evident as they advance their pipeline and seek effective solutions for patients waiting for new cancer medications.
FAQ
What is the market cap of Kinnate Biopharma (KNTE)?
What does Kinnate Biopharma Inc. specialize in?
What are Kinnate's lead product candidates?
Where is Kinnate Biopharma headquartered?
What recent achievements has Kinnate reported?
What strategic changes has Kinnate made recently?
What is Kinnate's financial condition?
What recent partnerships has Kinnate entered into?
How many employees does Kinnate plan to retain?
Where can I find more information about Kinnate Biopharma?
What is the Kinnate Discovery Engine?
